Edward joined ORI in 2019 as a Legal Counsel, and he heads the legal and compliance functions of ORI. These include fund formation, investment, portfolio management and disposal of investments. Before Edward’s legal career, he was a scientist at the Faculty of Medicine at the University of Hong Kong, where he obtained his Ph.D. With his background in both life sciences and law, he is also the head of the risk management committee which handles scientific, legal and financial risks of potential investments.

Some notable transactions handled by Edward include the disposal of Kymab Limited by ORI Healthcare Fund in 2021. Kymab Limited is a UK-based clinical-stage biopharmaceutical company that was sold to Sanofi at US $1.1 billion upfront, and up to US $350 million upon achievement of milestones. Kymab’s products target immune disorders, cancer and haematological diseases, and it potentially benefits millions of people worldwide.

Apart from legal and compliance functions, Edward is also a key personnel in ORI’s application to Invest Tokyo. This is a programme launched by the Tokyo Metropolitan Government to support foreign companies’ expansion to Tokyo. Invest Tokyo has granted financial incentives and technical support to ORI for setting up an office in Tokyo by 2023.

Outside of ORI, Edward is a founding director of the Biomedical Impact Association. This non-profit organisation was founded in 2022 to promote patient benefits, facilitate resource exchanges and assist biotechnological developments in Hong Kong. Edward is also a CUHK LAW Distinguished Professional Mentor to undergraduate law students.